Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 88.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,564 shares of the biotechnology company’s stock after selling 485,163 shares during the period. SG Americas Securities LLC’s holdings in Aurinia Pharmaceuticals were worth $562,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Aurinia Pharmaceuticals in the third quarter valued at approximately $3,330,000. AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at $1,155,000. Barclays PLC raised its stake in shares of Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after acquiring an additional 143,072 shares during the period. PDT Partners LLC boosted its position in Aurinia Pharmaceuticals by 76.0% during the 3rd quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock worth $2,210,000 after purchasing an additional 130,204 shares during the period. Finally, Algert Global LLC increased its holdings in Aurinia Pharmaceuticals by 106.8% in the 2nd quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock valued at $1,107,000 after purchasing an additional 100,104 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH stock opened at $7.95 on Friday. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The company has a market capitalization of $1.14 billion, a PE ratio of -53.00 and a beta of 1.24. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The firm has a fifty day simple moving average of $8.68 and a 200-day simple moving average of $7.46.

Insider Transactions at Aurinia Pharmaceuticals

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.